atazanavir accord 300 mg hard capsules
accord healthcare ireland ltd. - atazanavir sulfate - capsule, hard - 300 milligram(s) - atazanavir
atazanavir teva 150 mg
teva israel ltd - atazanavir as sulfate - capsules - atazanavir as sulfate 150 mg - atazanavir - atazanavir teva ® is indicated in combination with other antiretroviral agents for for the treatment of hiv-1 infection.
atazanavir teva 200 mg
teva israel ltd - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir teva ® is indicated in combination with other antiretroviral agents for for the treatment of hiv-1 infection.
atazanavir teva 300 mg
teva israel ltd - atazanavir as sulfate - capsules - atazanavir as sulfate 300 mg - atazanavir - atazanavir teva ® is indicated in combination with other antiretroviral agents for for the treatment of hiv-1 infection.
atazanavir accord 200 mg hard capsules
accord healthcare ireland ltd. - atazanavir sulphate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir
atazanavir teva 150 mg capsules, hard
teva b.v. - atazanavir sulfate - capsule, hard - 150 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years
atazanavir mylan
mylan pharmaceuticals limited - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir mylan, co-administered with low dose ritonavir, is indicated for the treatment of hiv 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years.the choice of atazanavir mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.
atazanavir teva capsules hard 150mg
teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 150 mg - antivirals for systemic use
atazanavir krka
krka, d.d., novo mesto - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations).the choice of atazanavir krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.
atazanavir capsule, gelatin coated
greenstone llc - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - atazanavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: atazanavir is contraindicated: table 6 displays drugs that are contraindicated with atazanavir. drug class drugs within class that are contraindicated with atazanavir clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if atazanavir is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such